Health
New drug reduces tumor volume and pain in patients with neurofibromatosis type 1 – News-Medical.Net
Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children’s Hospital of Philadelphia (CHOP) as part of the…
Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children’s Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1).
The results of the Phase 2 clinical trial, co-chaired by Michael J. Fisher, MD at CHOP, were published recently in Nature Medicine.
“This is the second…
-
Noosa News24 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
Business22 hours agoWhy the Betashares Nasdaq 100 ETF could be a perfect buy and hold pick
-
Business23 hours agoDoes Macquarie rate BHP shares a buy after its FY25 results?
-
General18 hours agoMigrants raise concerns over Australia’s English tests for visa applicants